Yen Near 40-Year Lows Despite BOJ Rate Hike, Markets Brace for Possible Intervention 
Trump Questions USMCA Renewal as Trade Talks Continue 
Oil Prices Steady as U.S.-Iran Truce Uncertainty and Middle East Tensions Keep Markets on Edge 
Trump Says No Hormuz Strait Tolls During 60-Day Iran Ceasefire 
Russia Stocks End Flat as MOEX Index Hits New 52-Week Low; Gold Falls and Oil Mixed 
100+ Global Companies Push Governments to Prioritize Electrification for Economic Growth 
Asian Stocks Surge as Oil Prices Fall and Strong US Dollar Weighs on Markets 
Canada, British Columbia Launch $5 Billion Infrastructure Partnership to Boost Housing, Transit, and Healthcare 
Oil Prices Slide as U.S.-Iran Deal and Hormuz Reopening Ease Supply Concerns 
China Keeps Loan Prime Rates Unchanged for 13th Straight Month as Policymakers Prioritize Credit Demand Recovery 
US Stock Futures Recover as Iran Signals Progress in Peace Talks 
Canada Imposes 10% Tariff on Canned Vegetable Imports to Protect Domestic Industry 
Japan Signals Readiness to Intervene as USD/JPY Nears 161 Amid Yen Weakness 
Gold Prices Slide as Hawkish Fed and Strong Dollar Weigh on Bullion 
Dollar Holds Firm as U.S.-Iran Talks Ease Tensions, GBP/USD Slips Amid UK Political Uncertainty 
Russian Stocks End Flat as MOEX Index Hits New 52-Week Low 
Swiss pharmaceutical leader Roche confirmed it has no plans for layoffs, emphasizing a healthy business outlook. CEO Thomas Schinecker highlighted steady research funding and workforce stability despite global economic challenges in Europe and China, as well as setbacks in cancer drug development.
Roche Maintains Workforce Stability Amid Market Challenges
Roche, a Swiss pharmaceutical corporation, does not intend to reduce its workforce, and the company's business is doing well. According to a statement made by CEO Thomas Schinecker, which was published in a Swiss publication on Sunday, Investing.com shares.
The stock price of Roche has dropped significantly below the highs it reached in April 2022, and the CEO was questioned about the company's plans for personnel in light of recent setbacks in the company's efforts to produce pharmaceuticals to cure a variety of illnesses, including cancer.
Schinecker responded to a question about whether or not the company was preparing to lay off employees by saying, "The number of workers is constant to slightly increasing," during an interview with the NZZ am Sonntag.
Research and Development Budgets Remain Steady
"I can say with certainty that we have a very healthy business. And we don't have a growth problem either," he remarked, pointing out that Roche's funding for research and development was consistent and not expanding. He also included this information in his statement.
When Schinecker was asked when Roche's intended anti-obesity medicine would be available for purchase, he responded that it may be as early as 2029 or perhaps earlier.
European Economic Struggles Create Headwinds for Recovery
While discussing the forecast for the coming year in a broader sense, particularly in light of the recent difficulties that the German economy has been experiencing, the CEO of Roche stated that Europe still faced problems.
"There's some economic growth in the United States, but things are more difficult in China at the moment," he explained to reporters. "And in Europe it will take some time before we get out of this."
